BridgeBio Pharma, Inc. (BBIO) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company focused on genetic diseases. The company's primary commercial product is Attruby (acoramidis) in the U.S. and Beyonttra (acoramidis) in the EU, UK, and Japan. The company maintains a late-stage pipeline including low-dose infigratinib (achondroplasia), encaleret (ADH1), and BBP-418 (LGMD2I/R9), for which an NDA was submitted to the FDA on March 30, 2026.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues, Net | $194,515 | $116,633 |
| Net Product Revenue | $180,596 | $36,739 |
| License and Services Revenue | $4,419 | $79,690 |
| Royalty Revenue | $9,500 | $204 |
| Net Loss | $(166,555) | $(169,608) |
| Net Loss Attributable to Common Stockholders | $(164,043) | $(167,422) |
| Cash and Cash Equivalents | $879,891 | $570,119 |
| Marketable Securities | $60,295 | $17,363 |
| Total Debt (Principal) | $2,505,000 | $1,872,500 |
| Deferred Royalty Obligations (Net) | $871,185 | $855,030 |
Material Changes vs. Prior Period
- Revenue Growth: Total net revenue increased by $77.9 million (67%) year-over-year. This was driven primarily by a $143.9 million increase in net product revenue from Attruby and Beyonttra, partially offset by a $75.3 million decrease in license and services revenue (due to the recognition of a $75.0 million regulatory milestone in Q1 2025).
- Expense Increases: Operating costs and expenses rose to $300.5 million from $221.0 million. Selling, general, and administrative (SG&A) expenses increased by $57.5 million, reflecting investments in commercialization. Research and development (R&D) expenses increased by $15.2 million.
- Debt Issuance: In January 2026, the company issued $632.5 million in 0.75% Convertible Senior Notes due 2033. Proceeds were used to repurchase $82.5 million of common stock and fund general corporate purposes.
- Stock Repurchases: The company repurchased 1,081,825 shares of common stock in January 2026 for approximately $82.5 million concurrently with the 2033 Notes offering.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue incurring operating and net losses for the foreseeable future. The company anticipates that cash, cash equivalents, and marketable securities ($940.2 million as of March 31, 2026) will fund operations for at least the next 12 months.
- Commercialization: Future revenue is expected to be driven by recurring net product revenue from Attruby and Beyonttra. The company is building a specialty sales force and commercial infrastructure.
- Key Risks:
- Commercial Success: Business is substantially dependent on the commercial success of Attruby and Beyonttra, including market acceptance and reimbursement.
- Regulatory Approval: Uncertainty remains regarding the approval of pipeline candidates (infigratinib, encaleret, BBP-418).
- Debt Obligations: Significant indebtedness ($2.5 billion in notes plus deferred royalty obligations) requires substantial cash for servicing. The 2027 Notes mature in March 2027.
- Third-Party Reliance: The company relies entirely on third parties for manufacturing and clinical trial conduct.
Investor Verification Checklist
- Attruby/Beyonttra Sales Trajectory: Verify the sustainability of the $180.6 million net product revenue run rate and the impact of potential pricing pressures or reimbursement changes.
- Debt Maturity Profile: Confirm the company's strategy for refinancing or repaying the $550 million 2027 Notes maturing in March 2027, given the current cash burn rate.
- Pipeline Milestones: Monitor the FDA review timeline for the BBP-418 NDA submitted in March 2026 and upcoming data readouts for infigratinib and encaleret.
- Deferred Royalty Obligations: Assess the impact of the $871 million deferred royalty obligations (Funding Agreement and Royalty Purchase Agreement) on future cash flows as sales volumes increase.
- Stock Repurchase Program: Note the May 6, 2026 approval of a new $500 million share repurchase program and its potential impact on liquidity.